Get the Stockscreener App
18.14
5.16%
0.89
Pre-market:
17.89
-0.25
-1.38%
Puretech Health Plc Adr stock is traded at $18.14, with a volume of 45,077.
It is up +5.16% in the last 24 hours and up +20.93% over the past month.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
See More
Previous Close:
$17.25
Open:
$18.5
24h Volume:
45,077
Relative Volume:
8.18
Market Cap:
$441.56M
Revenue:
$4.66M
Net Income/Loss:
$-110.22M
P/E Ratio:
-3.9751
EPS:
-4.5634
Net Cash Flow:
$-84.82M
1W Performance:
+7.02%
1M Performance:
+20.93%
6M Performance:
+2.05%
1Y Performance:
+2.72%
1-Day Range:
$17.77
$19.33
1-Week Range:
$17.11
$19.33
52-Week Range:
$14.50
$19.92
Puretech Health Plc Adr Stock (PRTC) Company Profile
Name
Puretech Health Plc Adr
Sector
Industry
Phone
-
Address
-
Compare PRTC vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRTC
Puretech Health Plc Adr
|
18.14 | 441.56M | 4.66M | -110.22M | -84.82M | -4.5634 |
VRTX
Vertex Pharmaceuticals Inc
|
423.92 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
701.42 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
783.50 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.11 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
293.86 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Puretech Health Plc Adr Stock (PRTC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
Puretech Health Plc Adr Stock (PRTC) Latest News
PureTech Health H2 Earnings Call Highlights - Yahoo Finance
PureTech Health (NASDAQ:PRTC) Posts Quarterly Earnings Results, Beats Estimates By $0.59 EPS - MarketBeat
[20-F] PureTech Health plc Files Annual Report (Foreign Issuer) | PRTC SEC FilingForm 20-F - Stock Titan
Earnings call transcript: PureTech Health’s mixed FY2025 results spark stock drop - Investing.com India
PureTech Health (PRTC) ends Nasdaq ADS listing, focuses trading on LSE - Stock Titan
PureTech to Exit Nasdaq Listing and Consolidise Trading in London - Yahoo Finance UK
PureTech Health to delist ADSs from Nasdaq, focus on LSE By Investing.com - Investing.com South Africa
PureTech Health to delist ADSs from Nasdaq, focus on LSE - Investing.com
PureTech Announces Annual Results for Year Ended December 31, 2025 - ChartMill
PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange - Business Wire
PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors - ChartMill
PureTech Health (PRTC) Expected to Announce Earnings on Wednesday - MarketBeat
PRTC.L Technical Analysis | Trend, Signals & Chart Patterns | PURETECH HEALTH PLC (LON:PRTC) - ChartMill
0VQ.DE Stock Price, Quote & Chart | PURETECH HEALTH PLC (FRA:0VQ) - ChartMill
PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) Short Interest Up 30.8% in March - MarketBeat
Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of Emerging Therapies | DelveInsight - GlobeNewswire Inc.
PureTech Founded Entity Seaport Therapeutics Announces Positive Proof of Concept Topline Results from Ongoing Phase 1 Trial of GlyphAgo™ in Healthy Volunteers - ChartMill
PureTech publishes phase 2b deupirfenidone IPF trial results - Investing.com
PRTC Stock Price, Quote & Chart | PURETECH HEALTH PLCADR (NASDAQ:PRTC) - ChartMill
Short Interest in PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) Rises By 140.8% - MarketBeat
Short Interest in Citizens Bancorp of Virginia, Inc. (OTCMKTS:CZBT) Grows By 141.4% - Defense World
Pacer American Energy Independence ETF (NYSEARCA:USAI) Sees Large Increase in Short Interest - Defense World
PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in Humans - ChartMill
Lansdowne Partners UK LLP Takes Position in PureTech Health PLC Sponsored ADR $PRTC - MarketBeat
PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) Short Interest Up 36.2% in February - MarketBeat
PureTech Health in the FTSE landscape as technical momentum shifts - Kalkine Media
PureTech to Present at the Leerink Partners Global Healthcare Conference - ChartMill
PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) Short Interest Update - MarketBeat
PureTech Health (NASDAQ:PRTC) Shares Up 2%Here's Why - MarketBeat
PRTC Stock Price and Chart — NASDAQ:PRTC - TradingView — Track All Markets
PureTech Health (NASDAQ:PRTC) Trading Up 5.7%Here's Why - MarketBeat
PureTech Health (NASDAQ:PRTC) Trading Up 5.7% – Here’s Why - Defense World
PureTech CEO to present at J.P. Morgan Healthcare Conference By Investing.com - Investing.com India
PureTech CEO to present at J.P. Morgan Healthcare Conference - Investing.com
PureTech to Present at 44th Annual J.P. Morgan Healthcare Conference - Chartmill
PureTech Health plc (OTCMKTS:PTCHF) Sees Significant Decrease in Short Interest - Defense World
PureTech Health appoints Robert Lyne as permanent CEO By Investing.com - Investing.com UK
PureTech Health appoints Robert Lyne as permanent CEO - Investing.com
PureTech Health (NASDAQ:PRTC) Trading Down 0.7% – Time to Sell? - Defense World
PureTech Health (NASDAQ:PRTC) Trading Down 0.7%Time to Sell? - MarketBeat
PureTech provides update on AGM results following shareholder concerns - Investing.com
PureTech stock falls after FDA meeting on IPF drug - Investing.com
PureTech Health (NASDAQ:PRTC) Trading 0.4% HigherStill a Buy? - MarketBeat
PureTech Health (NASDAQ:PRTC) Stock Price Up 3.1%Time to Buy? - MarketBeat
PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) Short Interest Up 100.0% in September - MarketBeat
PureTech Health Sees Strong Market Presence in FTSE All Share - Kalkine Media
What Makes PureTech Health (PRTC) a New Buy Stock - Yahoo Finance
BioHarvest Sciences (BHST) Short Interest & Short Float | Updated Dec 2025 - MarketBeat
PureTech launches new entity to advance IPF treatment deupirfenidone - Investing.com
PureTech Health to report half-yearly results on August 28 - Investing.com
PureTech Health announces board leadership transition - Investing.com
Puretech Health Plc Adr Stock (PRTC) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):